Insulin Aspart ELISA Kit

Name: Insulin Aspart ELISA Kit
SKU: DEIABL215
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Purified Antibody, Plasma, Serum

Detection Method

Competitive-ELISA

Intended Use

The Insulin Aspart ELISA Kit is a highly sensitive and specific tool for measuring the levels of Insulin Aspart in biological samples such as serum, plasma, and urine.

Contents of Kit

No.	Components	Size	Storage Conditions
1	Polystyrene microplate	96 wells × 1	-20°C
2	Standard - LyophilizedInsulin Aspart	5000 ng/vial × 2	-20°C
3	Detection A - Biotin labeled Insulin Aspart	60 μL × 1	-20°C
4	Detection B - Biotin labeled Insulin Aspart	120 μL × 1	20°C
5	Standard Diluent	25 mL × 1	4°C
6	Assay Diluent	25 mL × 1	4°C
7	20× Concentrated Wash Buffer	25 mL × 1	4°C
8	Color Reagent - Tetramethylbenzidine (TMB)	12 mL × 1	4°C
9	Stop Solution	6 mL × 1	4°C
10	Plate Adhesive Sealer	4 pieces

Storage

Stable for 6 months from the date of manufacture, if Capture Plate, Standard, Detection A and B are kept at -20°C. The remaining reagents can be stored at 4°C.

Citations

Have you cited DEIABL215 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

A pilot study comparing the CGM-assessed glycemic profiles of patients with type 1 diabetes on insulin degludec and insulin glargine

DIABETOLOGY INTERNATIONAL

Authors: Kuroda, Akio; Tsuruo, Miho; Aki, Nanako; Kondo, Takeshi; Oguro, Yukari; Tamaki, Motoyuki; Aihara, Ken-ichi; Endo, Itsuro; Matsumoto, Toshio; Abe, Masahiro; Matsuhisa, Munehide

Abstract

Aims To compare the diurnal glycemic profiles obtained with basal insulin degludec (InsDeg) and basal insulin glargine (InsGla) in patients with type 1 diabetes using continuous glucose monitoring (CGM) in an outpatient setting. Methods Twenty Japanese patients with type 1 diabetes who were using oncedaily InsGla before supper as part of their multiple daily insulin injections were consecutively recruited. CGM was initiated before supper on day 1, and InsGla was switched to InsDeg at the same dose on day 3. The average CGM glucose profile obtained on days 1 and 2 was compared with the corresponding profile for days 5 and 6. The bolus insulin regimen was not changed during the study period. Results CGM glucose was significantly higher (p<0.05) from 19: 30 to 22: 30 and significantly lower (p<0.05) from 6: 30 to 8: 00 with basal InsDeg than with basal InsGla. The duration of hypoglycemia (<70 mg/dl) was the same regardless of whether basal InsDeg or basal InsGla was used. Conclusions The peak in the action profile of InsDeg lasts longer and is possibly stronger than that of InsGla.

Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?

THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM

Authors: Biester, Torben; Kordonouri, Olga; Danne, Thomas

Abstract

For paediatric patients with type 1 diabetes, intensified insulin therapy with either multiple daily injection or insulin pump therapy is currently the only method of treatment. To optimize this therapy, insulin analogues are fixed parts of all therapy regimens. New ultra-rapid insulins seem to be beneficial not only in adults but also in this age group. New developments in long-acting analogues have demonstrated safety and will be regular in paediatrics, we hope, soon. Furthermore, the psychosocial approach for consideration of real-life aspects becomes more the focus of therapeutic regimens and is implemented into international guidelines. Technical improvements, such as continuous glucose monitoring, particularly in combination with pump therapy, support the great success of rapid-acting analogues by reducing hypoglycaemias. Non-insulin agents such as SGLT2-inhibitors show beneficial aspects in people with type 1 diabetes. For outpatient care with these currently off-label-used drugs, special training for measurement of ketones should be imperative.